Base de dados : MEDLINE
Pesquisa : D27.505.519.625.375.425.425 [Categoria DeCS]
Referências encontradas : 6986 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 699 ir para página                         

  1 / 6986 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28456772
[Au] Autor:Sano T; Utsumi D; Amagase K; Matsumoto K; Tominaga M; Higuchi K; Takeuchi T; Kato S
[Ad] Endereço:Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan. beatatsuo0507@gmail.com.
[Ti] Título:Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
[So] Source:J Physiol Pharmacol;68(1):79-90, 2017 Feb.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Intestinal mucositis accompanied by severe diarrhea is one of the most common side effects during cancer chemotherapy. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties via sensory afferent neurons, is used for the treatment of upper gastrointestinal diseases. The present study investigated the effects of lafutidine on 5-fluorouracil (5-FU)-induced intestinal mucositis induced in mice. Male C57BL/6 wild-type (WT), sensory deafferented mice, and transient receptor potential vanilloid subfamily 1 knockout (TRPV1KO) mice were used. Animals were administered 5-FU once daily, while lafutidine and famotidine were administered twice daily for 6 days. Repeated administration of 5-FU caused severe intestinal mucositis, characterized by shortening of villi and destruction of crypts and was accompanied by diarrhea and body weight loss. Daily administration of lafutidine reduced the severity of intestinal mucositis, diarrhea and body weight loss in a dose-dependent manner, while famotidine had no effect on intestinal mucositis. The preventive effects of lafutidine were completely abolished in sensory deafferented and TRPV1-KO mice. Lafutidine significantly suppressed 5-FU-increased MPO activity and inflammatory cytokine expression on day 6, but not apoptosis induction in intestinal crypts on day 1. Lafutidine induced Alcian Blue and PAS-positive mucus production in the small intestine. These findings suggest that lafutidine attenuates 5-FU-induced intestinal mucositis, most likely by increasing mucus production via activation of sensory afferent neurons. Furthermore, intact TRPV1 signaling is essential for the activation of sensory afferent neurons induced by lafutidine. Therefore, lafutidine is more useful than other common antacids for the treatment of intestinal mucositis during cancer chemotherapy.
[Mh] Termos MeSH primário: Acetamidas/uso terapêutico
Diarreia/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Mucosite/tratamento farmacológico
Piperidinas/uso terapêutico
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Acetamidas/farmacologia
Animais
Antimetabólitos Antineoplásicos
Diarreia/metabolismo
Diarreia/patologia
Famotidina/uso terapêutico
Fluoruracila
Antagonistas dos Receptores Histamínicos H2/farmacologia
Interleucina-1beta/genética
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Intestinos/patologia
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Mucosite/induzido quimicamente
Mucosite/patologia
Peroxidase/metabolismo
Piperidinas/farmacologia
Piridinas/farmacologia
RNA Mensageiro/metabolismo
Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetamides); 0 (Antimetabolites, Antineoplastic); 0 (Histamine H2 Antagonists); 0 (IL1B protein, mouse); 0 (Interleukin-1beta); 0 (Piperidines); 0 (Pyridines); 0 (RNA, Messenger); 0 (Tumor Necrosis Factor-alpha); 49S4O7ADLC (lafutidine); 5QZO15J2Z8 (Famotidine); EC 1.11.1.7 (Peroxidase); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  2 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29236753
[Au] Autor:Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
[Ad] Endereço:Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany.
[Ti] Título:Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
[So] Source:PLoS One;12(12):e0189521, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ranitidine (Zantac®) is a H2-receptor antagonist commonly used for the treatment of acid-related gastrointestinal diseases. Ranitidine was reported to be a substrate of the organic cation transporters OCT1 and OCT2. The hepatic transporter OCT1 is highly genetically variable. Twelve major alleles confer partial or complete loss of OCT1 activity. The effects of these polymorphisms are highly substrate-specific and therefore difficult to predict. The renal transporter OCT2 has a common polymorphism, Ala270Ser, which was reported to affect OCT2 activity. AIM: In this study we analyzed the effects of genetic polymorphisms in OCT1 and OCT2 on the uptake of ranitidine and on its potency to inhibit uptake of other drugs. METHODS AND RESULTS: We characterized ranitidine uptake using HEK293 and CHO cells stably transfected to overexpress wild type OCT1, OCT2, or their naturally occurring allelic variants. Ranitidine was transported by wild-type OCT1 with a Km of 62.9 µM and a vmax of 1125 pmol/min/mg protein. Alleles OCT1*5, *6, *12, and *13 completely lacked ranitidine uptake. Alleles OCT1*2, *3, *4, and *10 had vmax values decreased by more than 50%. In contrast, OCT1*8 showed an increase of vmax by 25%. The effects of OCT1 alleles on ranitidine uptake strongly correlated with the effects on morphine uptake suggesting common interaction mechanisms of both drugs with OCT1. Ranitidine inhibited the OCT1-mediated uptake of metformin and morphine at clinically relevant concentrations. The inhibitory potency for morphine uptake was affected by the OCT1*2 allele. OCT2 showed only a limited uptake of ranitidine that was not significantly affected by the Ala270Ser polymorphism. CONCLUSIONS: We confirmed ranitidine as an OCT1 substrate and demonstrated that common genetic polymorphisms in OCT1 strongly affect ranitidine uptake and modulate ranitidine's potential to cause drug-drug interactions. The effects of the frequent OCT1 polymorphisms on ranitidine pharmacokinetics in humans remain to be analyzed.
[Mh] Termos MeSH primário: Antagonistas dos Receptores Histamínicos H2/farmacocinética
Transportador 1 de Cátions Orgânicos/metabolismo
Transportador 2 de Cátion Orgânico/metabolismo
Polimorfismo Genético
Ranitidina/farmacocinética
[Mh] Termos MeSH secundário: Animais
Células CHO
Cricetulus
Células HEK293
Seres Humanos
Transportador 1 de Cátions Orgânicos/genética
Transportador 2 de Cátion Orgânico/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Organic Cation Transporter 1); 0 (Organic Cation Transporter 2); 884KT10YB7 (Ranitidine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189521


  3 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449186
[Au] Autor:Chen WC; Lin KH; Huang YT; Tsai TJ; Sun WC; Chuah SK; Wu DC; Hsu PI
[Ad] Endereço:Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
[Ti] Título:The risk of lower gastrointestinal bleeding in low-dose aspirin users.
[So] Source:Aliment Pharmacol Ther;45(12):1542-1550, 2017 06.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Aspirin increases the risk of gastrointestinal bleeding. AIM: To investigate the risk of lower gastrointestinal bleeding (LGIB) in aspirin users. METHODS: Low-dose (75-325 mg daily) aspirin users and controls matched by age, gender and enrollment time in a 1:5 ratio were selected from 1 million randomly sampled subjects in the National Health Insurance Research Database of Taiwan. Cox proportional hazard regression models were developed to evaluate the predictors of LGIB with adjustments for age, gender, comorbidities including coronary artery disease, ischaemic stroke, diabetes, hypertension, chronic kidney disease, liver cirrhosis, chronic obstructive pulmonary disease, dyslipidemia, uncomplicated peptic ulcer disease, history of peptic ulcer bleeding, and concomitant use of clopidogrel, ticlopidine, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, steroids, proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), nitrates, alendronate, selective serotonin reuptake inhibitors (SSRIs) and calcium channel blockers. RESULTS: A total of 53 805 aspirin users and 269 025 controls were included. Aspirin group had a higher incidence of LGIB within 1 year than control group (0.20% vs 0.06%, P<.0001). Aspirin (hazard ratio [HR]: 2.75, 95% confidence interval [CI]: 2.06-3.65), NSAIDs (HR: 8.61, 95% CI: 3.28-22.58), steroids (HR: 10.50, 95% CI: 1.98-55.57), SSRIs (HR: 11.71, 95% CI: 1.40-97.94), PPIs (HR: 8.47, 95% CI: 2.26-31.71), and H2RAs (HR: 10.83, 95% CI: 2.98-39.33) were significantly associated with LGIB. CONCLUSIONS: The risk of LGIB was higher in low-dose aspirin users than in aspirin nonusers in this nationwide cohort. Low-dose aspirin, NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for LGIB.
[Mh] Termos MeSH primário: Aspirina/administração & dosagem
Hemorragia Gastrointestinal/epidemiologia
Hemorragia Gastrointestinal/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anti-Inflamatórios não Esteroides/uso terapêutico
Aspirina/efeitos adversos
Estudos de Casos e Controles
Comorbidade
Inibidores de Ciclo-Oxigenase 2/uso terapêutico
Bases de Dados Factuais
Relação Dose-Resposta a Droga
Feminino
Hemorragia Gastrointestinal/induzido quimicamente
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Incidência
Masculino
Meia-Idade
Úlcera Péptica/complicações
Úlcera Péptica/tratamento farmacológico
Úlcera Péptica/epidemiologia
Úlcera Péptica Hemorrágica/tratamento farmacológico
Úlcera Péptica Hemorrágica/epidemiologia
Inibidores da Bomba de Prótons/uso terapêutico
Insuficiência Renal Crônica/complicações
Insuficiência Renal Crônica/tratamento farmacológico
Insuficiência Renal Crônica/epidemiologia
Fatores de Risco
Inibidores da Captação de Serotonina/uso terapêutico
Taiwan/epidemiologia
Ticlopidina/análogos & derivados
Ticlopidina/uso terapêutico
Varfarina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Cyclooxygenase 2 Inhibitors); 0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors); 0 (Serotonin Uptake Inhibitors); 5Q7ZVV76EI (Warfarin); A74586SNO7 (clopidogrel); OM90ZUW7M1 (Ticlopidine); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14079


  4 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28973122
[Au] Autor:Lyon J
[Ti] Título:Study Questions Use of Acid Suppressors to Curb Mild Infant Reflux.
[So] Source:JAMA;318(15):1427-1428, 2017 Oct 17.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Ósseas Metabólicas/induzido quimicamente
Refluxo Gastroesofágico/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H2/efeitos adversos
Inibidores da Bomba de Prótons/efeitos adversos
[Mh] Termos MeSH secundário: Esofagite Péptica/tratamento farmacológico
Esofagite Péptica/etiologia
Refluxo Gastroesofágico/complicações
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Lactente
Inibidores da Bomba de Prótons/uso terapêutico
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171004
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.12160


  5 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28947480
[Au] Autor:Kapur S; Barbhaiya C; Deneke T; Michaud GF
[Ad] Endereço:From Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (S.K.); Division of Cardiology, New York University Langone Medical Center, New York (C.B.); Heart Center Bad Neustadt, Germany (T.D.); and Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN
[Ti] Título:Esophageal Injury and Atrioesophageal Fistula Caused by Ablation for Atrial Fibrillation.
[So] Source:Circulation;136(13):1247-1255, 2017 Sep 26.
[Is] ISSN:1524-4539
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Esophageal perforation is a dreaded complication of atrial fibrillation ablation that occurs in 0.1% to 0.25% of atrial fibrillation ablation procedures. Delayed diagnosis is associated with the development of atrial-esophageal fistula (AEF) and increased mortality. The relationship between the esophagus and the left atrial posterior wall is variable, and the esophagus is most susceptible to injury where it is closest to areas of endocardial ablation. Esophageal ulcer seems to precede AEF development, and postablation endoscopy documenting esophageal ulcer may identify patients at higher risk for AEF. AEF has been reported with all modalities of atrial fibrillation ablation despite esophageal temperature monitoring. Despite the name AEF, fistulas functionally act 1 way, esophageal to atrial, which accounts for the observed symptoms and imaging findings. Because of the rarity of AEF, evaluation and validation of strategies to reduce AEF remain challenging. A high index of suspicion is recommended in patients who develop constitutional symptoms or sudden onset chest pain that start days or weeks after atrial fibrillation ablation. Early detection by computed tomography scan with oral and intravenous contrast is safe and feasible, whereas performance of esophageal endoscopy in the presence of AEF may result in significant neurological injury resulting from air embolism. Outcomes for esophageal stenting are poor in AEF. Aggressive intervention with skilled cardiac and thoracic surgeons may improve chances of stroke-free survival for all types of esophageal perforation.
[Mh] Termos MeSH primário: Fibrilação Atrial/patologia
Ablação por Cateter/efeitos adversos
Fístula Esofágica/etiologia
[Mh] Termos MeSH secundário: Fibrilação Atrial/tratamento farmacológico
Fibrilação Atrial/cirurgia
Fístula Esofágica/diagnóstico
Fístula Esofágica/epidemiologia
Esôfago/anatomia & histologia
Esôfago/lesões
Esôfago/fisiopatologia
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Prognóstico
Inibidores da Bomba de Prótons/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.1161/CIRCULATIONAHA.117.025827


  6 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28871989
[Au] Autor:McPartlin A; Swaminath A; Wang R; Pintilie M; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
[Ad] Endereço:Radiation Medicine Program, Princess Margaret Cancer Centre, and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
[Ti] Título:Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases.
[So] Source:Int J Radiat Oncol Biol Phys;99(2):388-395, 2017 Oct 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report mature outcomes of prospective phase 1 and 2 studies of stereotactic body radiation therapy (SBRT) for the treatment of colorectal liver metastases (CLMs). METHODS AND MATERIALS: Patients with histologically confirmed CLMs unsuitable for resection or standard therapies were eligible for sequential phase 1 and 2 studies conducted from 2003 to 2012. RESULTS: Of 60 patients treated, 82% had received previous chemotherapy, 23% had undergone previous focal liver treatment, and 38% had extrahepatic disease at the time of SBRT. The median number of gross tumor volume (GTV) targets per patient was 1 (range, 1-6), with a median total target volume of 117.7 cm (range, 6.7-3115.4 cm ). The median minimum dose to the GTV was 37.6 Gy (range, 22.7-62.1 Gy) in 6 fractions over a period of 2 weeks. Other than 1 case of grade 3 nausea, there were no acute toxicities greater than grade 2. With a median follow-up period of 28.1 months for survivors, no gastrointestinal bleed or biliary or liver toxicity was seen. The local control rate per lesion at 1 and 4 years was 49.8% and 26.2%, respectively. Increasing minimum dose to the GTV was associated with improved local control (P=.003). Median overall survival was 16.0 months (95% confidence interval, 11.9-20.5 months). On multivariate analysis, improved survival was associated with smaller total GTV (P=.017), performance status of 0 or 1 (P=.007), no extrahepatic disease at the time of treatment (P=.005), and local control of targeted liver disease (P=.001). Two long-term survivors remain disease free at 49 and 125 months. CONCLUSIONS: Six-fraction SBRT for CLM is safe and may be associated with long-term cure. Local control was significantly associated with delivered dose and was lower than seen in other studies using a higher SBRT dose. Survival was associated with smaller tumor volume, absence of extrahepatic disease, performance status of 0 or 1, and local control of treated liver lesions.
[Mh] Termos MeSH primário: Neoplasias do Colo/patologia
Neoplasias Hepáticas/radioterapia
Neoplasias Hepáticas/secundário
Radiocirurgia/métodos
Neoplasias Retais/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Fracionamento de Dose
Feminino
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Neoplasias Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Órgãos em Risco/efeitos da radiação
Estudos Prospectivos
Inibidores da Bomba de Prótons/uso terapêutico
Lesões por Radiação/prevenção & controle
Radiocirurgia/efeitos adversos
Carga Tumoral
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  7 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28836158
[Au] Autor:Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
[Ad] Endereço:Department of Internal Medicine, Bassett Medical Center, One Atwell Road, Cooperstown, NY, 13326, USA.
[Ti] Título:Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
[So] Source:Dig Dis Sci;62(10):2821-2827, 2017 Oct.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: The aim of this meta-analysis was to assess the risks of chronic kidney disease (CKD) and/or end-stage kidney disease (ESRD) in patients who are taking proton-pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs). METHODS: Comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through April 2017 to identify all studies that investigated the risks of CKD or ESRD in patients taking PPIs/H2RAs versus those without PPIs/H2RAs. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067252). RESULTS: Five studies with 536,902 participants were patients were identified and included in the data analysis. When compared with non-PPIs users, the pooled risk ratio (RR) of CKD or ESRD in patients with PPI use was 1.33 (95% CI 1.18-1.51). Pre-specified subgroup analysis (stratified by CKD or ESRD status) demonstrated pooled RRs of 1.22 (95% CI 1.14-1.30) for association between PPI use and CKD and 1.88 (95% CI 1.71-2.06) for association between PPI use and ESRD, respectively. However, there was no association between the use of H2RAs and CKD with a pooled RR of 1.02 (95% CI 0.83-1.25). When compared with the use of H2RAs, the pooled RR of CKD in patients with PPI use was 1.29 (95% CI 1.22-1.36). CONCLUSIONS: Our study demonstrates statistically significant 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in patients using H2RAs.
[Mh] Termos MeSH primário: Antagonistas dos Receptores Histamínicos H2/efeitos adversos
Falência Renal Crônica/induzido quimicamente
Inibidores da Bomba de Prótons/efeitos adversos
Insuficiência Renal Crônica/induzido quimicamente
[Mh] Termos MeSH secundário: Seres Humanos
Falência Renal Crônica/diagnóstico
Razão de Chances
Insuficiência Renal Crônica/diagnóstico
Medição de Risco
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-017-4725-5


  8 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28728964
[Au] Autor:Lochhead P; Hagan K; Joshi AD; Khalili H; Nguyen LH; Grodstein F; Chan AT
[Ad] Endereço:Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
[Ti] Título:Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.
[So] Source:Gastroenterology;153(4):971-979.e4, 2017 Oct.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Studies have reported associations between proton pump inhibitor (PPI) use and dementia. However, data are lacking on long-term PPI use and cognitive function. We therefore examined associations between PPI use and performance in tests of cognitive function. Because of shared clinical indications, we examined associations for H2 receptor antagonists (H2RAs) as a secondary aim. METHODS: We used prospectively collected data on medication use and other potential risk factors from 13,864 participants in the Nurses' Health Study II who had completed a self-administered computerized neuropsychological test battery. Multivariable linear regression models were used to examine associations between medication use and composite scores of psychomotor speed and attention, learning and working memory, and overall cognition. RESULTS: We observed a modest association between duration of PPI use and scores for psychomotor speed and attention (mean score difference for PPI use of 9-14 years vs never users, -0.06; 95% confidence interval, -0.11 to 0.00; P = .03). After controlling for H2RA use, the magnitude of this score difference was attenuated. Among individuals who did not use PPIs regularly, duration of H2RA use was associated with poorer cognitive scores, with the strongest association apparent for learning and working memory (mean score difference for H2RA users of 9-14 years vs never users, -0.20; 95% confidence interval, -0.32 to -0.08; P < .001). CONCLUSIONS: In an analysis of data from the Nurses' Health Study II, we did not observe a convincing association between PPI use and cognitive function. Our data do not support the suggestion that PPI use increases dementia risk. Because our primary hypothesis related to PPI use, our findings for H2RAs should be interpreted with caution.
[Mh] Termos MeSH primário: Transtornos Cognitivos/induzido quimicamente
Cognição/efeitos dos fármacos
Inibidores da Bomba de Prótons/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Atenção/efeitos dos fármacos
Transtornos Cognitivos/diagnóstico
Transtornos Cognitivos/psicologia
Esquema de Medicação
Feminino
Antagonistas dos Receptores Histamínicos H2/administração & dosagem
Antagonistas dos Receptores Histamínicos H2/efeitos adversos
Seres Humanos
Modelos Lineares
Memória/efeitos dos fármacos
Meia-Idade
Análise Multivariada
Testes Neuropsicológicos
Enfermeiras e Enfermeiros
Prognóstico
Estudos Prospectivos
Inibidores da Bomba de Prótons/administração & dosagem
Desempenho Psicomotor/efeitos dos fármacos
Medição de Risco
Fatores de Risco
Fatores Sexuais
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE


  9 / 6986 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28583827
[Au] Autor:Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
[Ad] Endereço:Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
[Ti] Título:Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
[So] Source:Gastroenterology;153(3):702-710, 2017 Sep.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with acute kidney injury and recent studies suggest that they may be associated with the risk of chronic kidney disease (CKD). METHODS: We performed a retrospective analysis using the Stockholm creatinine measurements database, which contains information on diagnoses, dispensation claims, and laboratory test results for all citizens in the Stockholm region from 2007 through 2010. We identified new users of PPIs (n = 105,305) and new users of H blockers (H B; n = 9578); data on renal outcomes were collected for a median 2.7 years. The primary outcome was progression CKD, defined as doubling of creatinine or decrease in estimated glomerular filtration rate of 30% or more. Secondary outcomes were end-stage renal disease and acute kidney injury. Complete collection of repeated PPI and H B dispensations at pharmacies in Sweden allowed modeling the time-dependent risk associated with cumulative PPI exposure. RESULTS: Users of PPIs, compared with users of H Bs, had an increased risk for doubled levels of creatinine (1985 events; adjusted hazard ratio [HR], 1.26; 95% CI, 1.05-1.51) and decrease in estimated glomerular filtration rate of 30% or more (11,045 events; 1.26; 95% CI, 1.16-1.36). PPI use also associated with development of end-stage renal disease (HR, 2.40; 95% CI, 0.76-7.58) and acute kidney injury (HR, 1.30; 95% CI, 1.00-1.69). There was a graded association between cumulative exposure to PPIs and risk of CKD progression. This was not the case for cumulative H B use. CONCLUSIONS: Initiation of PPI therapy and cumulative PPI exposure is associate with increased risk of CKD progression in a large, North European healthcare system. Although consistent, the association was modest in magnitude, and cannot exclude residual confounding.
[Mh] Termos MeSH primário: Creatinina/sangue
Progressão da Doença
Inibidores da Bomba de Prótons/uso terapêutico
Insuficiência Renal Crônica/fisiopatologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/epidemiologia
Adulto
Idoso
Feminino
Seguimentos
Taxa de Filtração Glomerular
Antagonistas dos Receptores Histamínicos H2/uso terapêutico
Seres Humanos
Falência Renal Crônica/epidemiologia
Masculino
Meia-Idade
Insuficiência Renal Crônica/sangue
Estudos Retrospectivos
Fatores de Risco
Suécia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE


  10 / 6986 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28512370
[Au] Autor:Herrera-Mozo I; Sanz-Gallen P; Martí-Amengual G
[Ad] Endereço:Clinica Creu Blanca, Barcelona, Spain (Unit of Allergy). herreramozo.i@gmail.com.
[Ti] Título:Occupational contact allergy to omeprazole and ranitidine.
[Ti] Título:Occupational contact allergy to omeprazole and ranitidine..
[So] Source:Med Pr;68(3):433-435, 2017 May 16.
[Is] ISSN:0465-5893
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae. We report a case of occupational contact allergy to omeprazole and ranitidine. A 48-year-old man, with no pre-existing history of atopy or lifestyle factors. He neither had any medical history of consumption of drugs such as ranitidine and omeprazole. He worked for 19 months in the pharmaceutical company that manufactured ranitidine base. He presented rash in the face and eczema on the dorsum of the hands with itching. The study by prick tests with ranitidine gave negative response. Patch testing with ranitidine base and ranitidine hydrochloride gave positive response. A month later, when the patient was asymptomatic he returned to the pharmaceutical company, being switched from this previous job to the reactor manufacturing omeprazole. A few days after that, he presented erythematous eruptions involving face and neck with itching. Prick tests, path tests and in vitro laboratories studies with omeprazole gave positives. In this case the patient presented hypersensitivity type I at omeprazole and hypersensitivity type IV at omeprazole and ranitidine. Our aportation indicates the importance of careful analysis of the occupational exposure histories of patients with the suspected type I or type IV hypersensitivity to allergens, to determine whether work exposure is the cause. Med Pr 2017;68(3):433-435.
[Mh] Termos MeSH primário: Dermatite Ocupacional/diagnóstico por imagem
Antagonistas dos Receptores Histamínicos H2/efeitos adversos
Omeprazol/efeitos adversos
Inibidores da Bomba de Prótons/efeitos adversos
Ranitidina/efeitos adversos
[Mh] Termos MeSH secundário: Eczema/induzido quimicamente
Exantema/induzido quimicamente
Seres Humanos
Masculino
Meia-Idade
Testes do Emplastro
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H2 Antagonists); 0 (Proton Pump Inhibitors); 884KT10YB7 (Ranitidine); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE



página 1 de 699 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde